文献速递血栓与止血

人血浆源性凝血因子VIII与不同重组产品的N-糖基化深度比较:从结构到临床意义

In-depth comparison of N-glycosylation of human plasma-derived factor VIII and different recombinant products: from structure to clinical implications.
PubMed 文献 · J Thromb Haemost · 2018-06-11

本研究对人血浆源性凝血因子VIII(pdFVIII)与6种在CHO、BHK或HEK细胞系表达的重组FVIII(rFVIII)产品进行头对头糖组学和糖蛋白组学比较。结果首次在pdFVIII上发现N-羟乙酰神经氨酸(NeuGc),各rFVIII产品整体N-聚糖含量与pdFVIII显著不同,部分重组产品表达独特且具免疫学相关性的表位,HEK细胞表达的rFVIII与pdFVIII糖组差异最大。

要点

  • 首次在血浆源性FVIII上发现N-羟乙酰神经氨酸(NeuGc)。
  • 各rFVIII产品整体N-聚糖含量与pdFVIII显著不同,但位点特异性糖基化一致。
  • 部分rFVIII表达独特免疫相关表位,HEK表达产品差异最大。

核心结论

  • 各rFVIII产品整体N-聚糖含量与pdFVIII显著不同,部分重组产品表达独特且具免疫学相关性的表位,HEK细胞表达的rFVIII与pdFVIII糖组差异最大。

研究设计与样本

  • 对pdFVIII与6种在CHO、BHK或HEK细胞系表达、B结构域缺失程度不同的rFVIII产品进行头对头糖组学和糖蛋白组学表征,采用MALDI-MS与MS/MS、GC-MS和UPLC-UV-MSE技术组合。

主要发现

  • 首次提供pdFVIII上存在N-羟乙酰神经氨酸(NeuGc)的证据。
  • rFVIII的位点特异性糖基化与pdFVIII一致,不依赖于表达系统。
  • 各样本整体N-聚糖含量显著不同。
  • 各样本共有的生物学重要表位(即唾液酸化与高甘露糖)比例存在差异。
  • 部分重组产品表达独特且具免疫学相关性的表位,如LacdiNAc(LDN)、岩藻糖基化LacdiNAc(FucLDN)、NeuGc、LewisX/Y和Galα1,3 Gal表位。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Essentials Glycosylation heterogeneity of recombinant proteins affects pharmacokinetics and immunogenicity. N-glycomics/glycoproteomics of plasma-derived Factor VIII and 6 recombinant FVIIIs were compared. Depending on cell line, significant differences to plasma-derived FVIII were observed. Recombinant FVIIIs expressed distinct and immunologically relevant epitopes. SUMMARY: Background/Objective Human factor VIII (FVIII) is a plasma glycoprotein, defects of which result in hemophilia A. Current substitution therapy uses FVIII products purified from human plasma or from various cell lines (recombinant FVIII) with different levels of B-domain deletion. Glycosylation is a post-translational protein modification in FVIII that has a substantial influence on its physical, functional and antigenic properties. Variation in glycosylation is likely to be the reason that FVIII products differ in their pharmacokinetics, pharmacodynamics and immunogenicity. However, the literature on FVIII glycosylation is inconsistent, preventing assembly into a coherent model. Seeking to better understand the glycosylation mechanisms underlying FVIII biology, we studied the N-glycosylation of human plasma-derived (pd)FVIII and six rFVIII products expressed in CHO, BHK or HEK cell lines. Methods FVIII samples were subjected to head-to-head detailed glycomic and glycoproteomic characterization using a combination of MALDI-MS and MS/MS, GC-MS and UPLC-UV-MSE technologies. Results/Conclusion The results of our study detail the N-glycan repertoire of pdFVIII to an unprecedented level, and for the first time, provide evidence of N-glycolylneuraminic acid (NeuGc) found on pdFVIII. Although site-specific glycosylation of rFVIII proved consistent with pdFVIII regardless of the expression system, the entire N-glycan content of each sample appeared significantly different. Although the proportion of biologically important epitopes common to all samples (i.e. sialylation and high-mannose) varied between samples, some recombinant products expressed distinct and immunologically relevant epitopes, such as LacdiNAc (LDN), fucosylated LacdiNAc (FucLDN), NeuGc, LewisX/Y and Galα1,3 Gal epitopes. rFVIII expressed in HEK cells showed the greatest glycomic differences to human pdFVIII.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Canis K, Anzengruber J, Garenaux E, et al. In-depth comparison of N-glycosylation of human plasma-derived factor VIII and different recombinant products: from structure to clinical implications. J Thromb Haemost. 2018. PMID: 29888865. doi:10.1111/jth.14204

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。